Cargando…

Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice

BACKGROUND: Suppression of cardiac iinflammasome, which can be inhibited by Farnesoid X receptor (FXR) agonist, can ameliorate cardiac inflammation and fibrosis. Increased cardiac inflammasome decrease the abundance of regulatory T (Treg) cells and exacerbate cardiac dysfunction. Interaction between...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Szu-Yu, Huang, Chia-Chang, Yang, Ying-Ying, Huang, Shiang-Fen, Lee, Tzung-Yan, Li, Tzu-Hao, Hou, Ming-Chih, Lin, Han-Chieh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733885/ https://www.ncbi.nlm.nih.gov/pubmed/36490253 http://dx.doi.org/10.1371/journal.pone.0276717

Ejemplares similares

SIRT1-dependent mechanisms and effects of resveratrol for amelioration of muscle wasting in NASH mice
por: Liu, Chih-Wei, et al.
Publicado: (2020)

Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice
por: Tsai, Hung-Cheng, et al.
Publicado: (2019)

Pioglitazone Ameliorates Acute Endotoxemia-Induced Acute on Chronic Renal Dysfunction in Cirrhotic Ascitic Rats
por: Liu, Szu-Yu, et al.
Publicado: (2021)

Propranolol Suppresses the T-Helper Cell Depletion-Related Immune Dysfunction in Cirrhotic Mice
por: Tsai, Hung-Cheng, et al.
Publicado: (2020)

Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl(4)-Induced NASH Mice and the Effect of Obeticholic Acid
por: Zhu, Nanlin, et al.
Publicado: (2021)

Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model
por: Anfuso, Beatrice, et al.
Publicado: (2020)

Intestinal SIRT1 Deficiency-Related Intestinal Inflammation and Dysbiosis Aggravate TNFα-Mediated Renal Dysfunction in Cirrhotic Ascitic Mice
por: Chou, Yu-Te, et al.
Publicado: (2021)

miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
por: Rodrigues, Pedro M, et al.
Publicado: (2017)

miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
por: Rodrigues, Pedro M, et al.
Publicado: (2017)

Non-Selective Beta-Blockers Decrease Infection, Acute Kidney Injury Episodes, and Ameliorate Sarcopenic Changes in Patients with Cirrhosis: A Propensity-Score Matching Tertiary-Center Cohort Study
por: Li, Tzu-Hao, et al.
Publicado: (2021)

Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr‐/‐.Leiden Mice
por: Morrison, Martine C., et al.
Publicado: (2018)

A Pilot Genome‐Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH
por: Gawrieh, Samer, et al.
Publicado: (2019)

Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat
por: Zhang, Hanlin, et al.
Publicado: (2021)

Obeticholic acid ameliorates severity of Clostridioides difficile infection in high fat diet-induced obese mice
por: Jose, Shinsmon, et al.
Publicado: (2020)

Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes
por: McIlvride, Saraid, et al.
Publicado: (2019)

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
por: Lin, Chuangzhen, et al.
Publicado: (2022)

Nonalcoholic steatohepatitis (NASH) is associated with cardiac remodeling and dysfunction
por: Simon, Tracey G., et al.
Publicado: (2017)

Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice
por: Li, Shengjie, et al.
Publicado: (2022)

Urinary fatty acid and retinol binding protein-4 predict CKD progression in severe NAFLD patients with hypertension: 4-year study with clinical and experimental approaches
por: Tsai, Yu-Lien, et al.
Publicado: (2020)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

Notopterol Ameliorates Hyperuricemia-Induced Cardiac Dysfunction in Mice
por: Wang, Qian, et al.
Publicado: (2023)

Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2019)

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
por: Roth, Jonathan D., et al.
Publicado: (2019)

Chronic calcitriol supplementation improves the inflammatory profiles of circulating monocytes and the associated intestinal/adipose tissue alteration in a diet-induced steatohepatitis rat model
por: Su, Yen-Bo, et al.
Publicado: (2018)

Propranolol Is Associated with Lower Risk of Incidence of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Tertiary-Center Study and Indirect Comparison with Meta-Analysis
por: Li, Tzu-Hao, et al.
Publicado: (2020)

Ivabradine Ameliorates Cardiac Diastolic Dysfunction in Diabetic Mice Independent of Heart Rate Reduction
por: Xie, Hao, et al.
Publicado: (2021)

27558 Obeticholic acid (OCALIVA ®) protects against 2,8-dihydroxyadenine nephropathy in mice
por: Jones, Bryce, et al.
Publicado: (2021)

TLR4/CD14 Variants-Related Serologic and Immunologic Dys-Regulations Predict Severe Sepsis in Febrile De-Compensated Cirrhotic Patients
por: Fan, Wen-Chien, et al.
Publicado: (2016)

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
por: Roy, Partho Pratik, et al.
Publicado: (2022)

Clarification of Obeticholic Acid Dosing: Response to “Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation” by Quigley et al.
por: Feng, Cynthia
Publicado: (2018)

Obeticholic Acid Protects against Gestational Cholestasis-Induced Fetal Intrauterine Growth Restriction in Mice
por: Chen, Wei, et al.
Publicado: (2019)

Alpha-ketoglutarate ameliorates pressure overload-induced chronic cardiac dysfunction in mice
por: An, Dongqi, et al.
Publicado: (2021)

Correction: SIRT1-dependent mechanisms and effects of resveratrol for amelioration of muscle wasting in NASH mice
Publicado: (2020)

Mitochondrial Dysfunction in the Transition from NASH to HCC
por: Léveillé, Mélissa, et al.
Publicado: (2019)

The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression
por: Benegiamo, Giorgia, et al.
Publicado: (2023)

Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH
por: Fredrickson, Gavin, et al.
Publicado: (2021)

Lactobacillus paragasseri BBM171 Ameliorates Allergic Airway Inflammation Induced by Ovalbumin in Mice via Modulating the Th1/Th2 Balance
por: Cheng, Shih-Hsuan, et al.
Publicado: (2022)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p75kuons0ckf29tg1gavh3agbg